Form 424B5 - Prospectus [Rule 424(b)(5)]
July 08 2024 - 9:57PM
Edgar (US Regulatory)
Filed
Pursuant to Rule 424(b)(5)
Registration
No. 333-269183
SUPPLEMENT
NO. 1 TO
PROSPECTUS
SUPPLEMENT DATED JUNE 27, 2024
(To
Prospectus dated January 11, 2023) |
THE
SINGING MACHINE COMPANY, INC.
Up
to $2,020,000
COMMON
STOCK
This
prospectus supplement supplements, modifies and supersedes, only to the extent indicated herein, certain information contained in our
prospectus supplement dated June 27, 2024, which together with the prospectus dated January 11, 2023 contained in our Registration Statement
on Form S-3 (Registration No. 333-269183), we refer to as the prospectus, relating to the issuance and sale of our common stock, par
value $0.01 per share, from time to time through our sales agent Ascendiant Capital Markets, LLC, or ACM. These sales, if any, will be
made pursuant to the terms of the At-The-Market Sales Agreement, or the Sales Agreement, we entered into with ACM.
This
prospectus supplement should be read in conjunction with, is not complete without, and may not be delivered or utilized except in connection
with, the prospectus, including all supplements thereto and documents incorporated by reference therein. If there is any inconsistency
between the information in the prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.
Any information that is modified or superseded in the prospectus shall not be deemed to constitute a part of the prospectus, except as
modified or superseded by this prospectus supplement.
The
aggregate market value of our outstanding common stock held by non-affiliates is approximately $6,066,453 based on 7,883,131 shares of
outstanding common stock, of which 4,690,261 shares are held by affiliates, and a per share price of $1.90, which was the closing sale
price of our common stock as quoted on The Nasdaq Capital Market on June 10, 2024. As of the date of this prospectus supplement, we have
sold $1,077,241 of securities pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to, and including,
the date of this prospectus supplement, and are therefore eligible to sell up to an additional $940,000 of our securities pursuant to
General Instruction I.B.6 of Form S-3. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities registered
on the registration statement of which this prospectus supplement is a part with a value of more than one-third of the aggregate market
value of our common stock held by non-affiliates in any 12-month period, so long as the aggregate market value of our common stock held
by non-affiliates is less than $75,000,000.
We
are filing this prospectus supplement to supplement and amend, as of July 8, 2024, the prospectus, as supplemented, to increase the maximum
aggregate offering price of our common stock that may be offered, issued and sold under the prospectus, as supplemented and amended by
this prospectus supplement, pursuant to the Sales Agreement from $1,080,000 to $2,020,000. From and after the date hereof, pursuant to
General Instruction I.B.6 of Form S-3, we are offering to issue and sell up to $2,020,000 from time to time through ACM, acting as our
sales agent or principal in accordance with the Sales Agreement, as amended.
Our
common stock is listed on The Nasdaq Capital Market under the symbol “MICS”. The closing price of our common stock on July
8, 2024 was $1.19 per share.
Sales
of our common stock, if any, under this prospectus supplement will be made in sales deemed to be an “at the market offering”
as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. ACM is not required to
sell any specific amount of securities but will act as our sales agent using commercially reasonable efforts consistent with its normal
trading and sales practices, on mutually agreed terms between ACM and us. There is no arrangement for funds to be received in any escrow,
trust or similar arrangement.
The
compensation to ACM for sales of common stock sold pursuant to the Sales Agreement will be up to 3% of the gross proceeds of any shares
of common stock sold under the Sales Agreement. In connection with the sale of the common stock on our behalf, ACM will be deemed to
be an “underwriter” within the meaning of the Securities Act and the compensation of ACM will be deemed to be underwriting
commissions or discounts. We have also agreed to provide indemnification and contribution to ACM with respect to certain liabilities,
including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended, or the Exchange Act.
Investing
in our securities involves a high degree of risk. Before buying any of our securities, you should carefully consider the risk factors
described in “Risk Factors” on page S-9 of the prospectus supplement dated June 27, 2024, and under similar headings in other
documents that are incorporated by reference into this prospectus supplement and the prospectus.
Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined
if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.
The
date of this prospectus supplement is July 9, 2024.
Singing Machine (NASDAQ:MICS)
Historical Stock Chart
From Oct 2024 to Nov 2024
Singing Machine (NASDAQ:MICS)
Historical Stock Chart
From Nov 2023 to Nov 2024